Company news

Cynata Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cynata Awarded Grant for Coronary Artery Disease Study

October 27, 2019

Notice of Allowance from CIPO for Patent Application

October 24, 2019

September 2019 Quarterly Report

October 23, 2019

Cynata & Sumitomo Withdraw from Acquisition Discussions

October 16, 2019

CYP Advances Towards Osteoarthritis Phase 2 Clinical Trial

October 2, 2019

Cynata Receives US$3 million Fujifilm License Fee

September 25, 2019

Fujifilm Exercises License Option in GvHD

September 17, 2019

Update on Discussions with Sumitomo and Fujifilm

August 14, 2019

Response to ASX Aware Query

July 24, 2019

Response to ASX Price and Volume Query

July 19, 2019

Cynata confirms receipt of indicative non-binding proposal

July 18, 2019

June 2019 Quarterly Report

July 4, 2019

Cynata Strengthens Board & Executive Management Team

May 19, 2019

March 2019 Quarterly Report

April 26, 2019

Cynata Extends FUJIFILM Licence Option in GvHD

March 20, 2019

Cynata Receives Favourable Advice on Planned CLI Trial

March 11, 2019

December 2018 Quarterly Report

January 29, 2019

CYP Receives Notice of Acceptance from Aust Patent Office

January 6, 2019

Cynata Completes Clinical Study Report for Phase 1 Trial of CYP-001 in GvHD

December 18, 2018

Cynata Completes Clinical Study Report in GvHD

December 17, 2018

NHMRC to Fund Major Phase 2 Clinical Trial of Cynata’s Cymerus™ MSCs in Patients with Osteoarthritis

December 13, 2018

NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs

December 12, 2018

Cynata Receives $1.3m R&D Tax Incentive Refund

November 18, 2018

CYP Receives Notice of Allowance from European Patent Office

November 6, 2018

September 2018 Quarterly Report

October 23, 2018

Engineered Cymerus™ MSCs Demonstrate Anti-Cancer Effects in Preclinical Studies

October 18, 2018

MSCs Demonstrate Anti-Cancer Effects in Pre-Clinical Studies

October 17, 2018

Cynata MSCs Ameliorate CRS in Preclinical Study

September 19, 2018

Cynata Advances to Official Meeting with Japanese PMDA

September 2, 2018

Cynata GvHD Trial Meets all Safety & Efficacy Endpoints

August 29, 2018

Appendix 4E & Financial Statements

August 22, 2018

Cymerus MSCs improve cardiac recovery in preclinical study

July 30, 2018

June 2018 Quarterly Report

July 11, 2018

Cynata Enters Development Partnership with RCSI

July 1, 2018

Product Development Program Update & Investor Presentation

June 25, 2018

Positive 28-day Clinical Trial Data in Cohort B

June 20, 2018

Research Collaboration with UNSW for Coronary Artery Disease

June 18, 2018

Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD

June 11, 2018

Cynatas MSCs Effective in Model of Diabetic Wounds

May 30, 2018

$5.2m placement of shares to Fidelity International

May 29, 2018

Enrolment Completed in Cynatas Phase 1 Clinical Trial

May 23, 2018

Notice of Allowance from EPO for Patent Application

May 7, 2018

March 2018 Quarterly Report

April 27, 2018

CYP Completes Patent Application related to CAR-T Therapy

April 19, 2018

Further US Patent Granted for Cynata Cymerus Technology

April 10, 2018

FDA Grants Orphan Drug Designation to Cyanta for CYP-001

March 27, 2018

Excellent Data from Final Preliminary Evaluation Period

February 26, 2018

Cynata Engineered MSC Study Review Reveals Promising Results

February 4, 2018

December 2017 Quarterly Report

January 30, 2018

Cynata Treats First Patient in Cohort B

January 23, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 39 decks. Every deck is listed under its year.